Tech Entrepreneur Deepinder Goyal Faces Criticism Over New Brain Wearable

Tech entrepreneur Deepinder Goyal, co-founder of food delivery platform Zomato and Blinkit, has sparked a heated debate within the medical community following the introduction of a new wearable device called Temple. Marketed as a tool to monitor brain health by tracking blood circulation patterns, the device has drawn sharp criticism from doctors who question its scientific validity and high price point.

Priced at Rs 85,000 and available for pre-order, the device is designed to be placed on either side of the forehead. Mr. Goyal has promoted the gadget as a major advancement in preventive health technology, suggesting it could eventually serve as a personal device for monitoring physiological conditions. The product launch has even featured endorsements from public figures like cricket player Shubman Gill.

However, medical experts have raised significant concerns regarding the gadget's claims. Dr. Cyriac Abby Philips, a hepatologist and public health expert widely known as The Liver Doc, strongly criticized the product on social media, dismissing it as a scam. According to medical critics, the device measures blood flow and flushing in the superficial skin and scalp around the temple region rather than actual cerebral circulation inside the brain.

Physicians point out that the central scientific assertions behind the product have not been verified through peer-reviewed studies. Because human blood circulation is complex and influenced by various factors such as posture, blood pressure, and physical activity, medical professionals argue that superficial vascular signals cannot accurately indicate brain cell damage or cognitive aging.

The controversy highlights a broader discussion about the growing wellness economy and the marketing of health technologies directly to consumers. Critics note that devices monitoring biological metrics can sometimes generate unnecessary anxiety or offer false reassurance, which cannot replace a formal medical evaluation by a licensed healthcare provider.

While proponents argue that private investment in health innovation is necessary, medical specialists emphasize that companies entering the healthcare space must prioritize clinical validation and accountability over aggressive marketing strategies. Independent scientific trials and transparent research are essential before introducing predictive health tools to the public market.